Close Menu

Adaptive Biotechnologies

The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology. 

The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL. 

The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies. 

Pages